Here are the biggest calls on Wall Street on Monday:
Truist reiterates CoreWeave at Buy
The firm raised its price target to $165 per share from $155.
“We expect CRWV’s higher pricing to largely flow through to margins in 2H26 as NVIDIA’s increases are expected to affect systems shipped early next year.”
Wells Fargo reiterates Marvell at Outperform
Wells Fargo raised its price target on Marvell ahead of earnings on Tuesday.
“PT to $310 (was $240), ~28x our +$11/sh. FY29 EPS upside view.”
Evercore ISI adds Dell to Tactical Outperform List
Evercore ISI says it is bullish on Dell ahead of earnings on Sept. 1.
“We believe the setup remains attractive despite the recent runup in stock price. In our view, the debate has shifted from ‘is the AI infrastructure demand real’ to ‘how much can DELL physically ship’ and we expect DELL to print a solid beat and raise its FY27 guidance.”
UBS upgrades Celestica to Buy from Neutral
UBS says it sees “AI-driven demand.”
“We upgrade Celestica to Buy from Neutral and raise our price target to $430.”
Wells Fargo downgrades Canada Goose to Underweight from Overweight
Wells Fargo says it is concerned about El Niño’s impact on Canada Goose.
“Cut numbers below Street and downgrade to UW (from OW). While we appreciate the work done over the past 18-24 months to reinvest and improve product - we simply feel the macro is against them (El Niño, EMEA and tariffs) and the NT risk is material.”
Mizuho initiates Talen Energy at Outperform
Mizuho says the nuclear company has a differentiated offering.
“We are initiating coverage of Talen Energy at Outperform, with a $405 price target.”
Mizuho initiates Vistra at Outperform
Mizuho says the company is best positioned to benefit from rising electricity demand.
“We are initiating coverage on Vistra Corp. (VST) with an Outperform rating and a $169 price target, reflecting our view that VST is among the best-positioned merchant power platforms to monetize the structural step-change in U.S. electricity demand driven by AI and data center build-outs.”
Comments